“Extended Half-life Factor Products in the Management of Hemophilia,” a new online education opportunity from Medscape, is now available. This activity is part of Clinical Advances in Hemophilia: Management for Life, an educational series provided by leading bleeding disorders clinicians. The overarching goal of the program is to increase the knowledge, skills and competence of clinicians in providing individualized management of hemophilia.
The purpose of this activity, which is intended for hematologists, pediatricians, nurses and other healthcare professionals who treat patients with hemophilia, is to discuss the role of extended half-life factor products in hemophilia management, including data and clinical experience.
Upon completion, participants will be able to:
1. Evaluate updates in clinical trial data of extended half-life factor products for the treatment of hemophilia
2. Assess the optimal use of extended half-life factor products for the management of hemophilia, including identifying appropriate candidates, monitoring effectiveness and identifying inhibitor
The series is presented through a strategic collaboration between the National Hemophilia Foundation and Medscape Education Hematology, and supported by an independent educational grant from Biogen. After completing the activities within this program, available for one year from their release date, those eligible may receive free continuing education (CE) or continuing medical education (CME) credits.
Extended Half-life Factor Products in the Management of Hemophilia CME/CE
Craig Kessler, MD; Steven Pipe, MD; Ellis Neufeld, MD, PhD; Kim Schafer, RN, MSN
CME/CE Released: 09/24/2015; Valid for credit through 09/24/2016
Access this and other available educational activities by visiting Medscape.org, where registration is straightforward and free of charge. Once registered, you may access Clinical Advances in Hemophilia: Management for Life.
